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In a population-based study of 613 cases and 1082 controls, alcohol dehydrogenase 1B (ADH1B) genotype was not an independent
risk factor for breast cancer, athough the possibility was raised that it modifies risk associated with high levels of alcohol consumption
(OR 1.1, 95% confidence interval (CI) 0.8–1.6 for ADH1B*1/*1 genotype vs 0.2, 95% CI 0.1–1.0 for ADH1B*2 carriers).
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Alcohol consumption is one of the few modifiable risk factors for
breast cancer (Singletary and Gapstur, 2001; Collaborative Group
on Hormonal Factors in Breast Cancer, 2002), and we also
observed a dose-dependent effect of alcohol intake on breast
cancer risk in a case–control study of women up to age 50 years in
Germany (Kropp et al, 2001). However, drinking behaviour as well
as susceptibility to alcohol-induced carcinogenesis may be
influenced by individual genetic make-up. In this context, class I
alcohol dehydrogenases (ADHs), which are important enzymes in
the major pathway of alcohol metabolism in vivo and are
expressed in normal mammary epithelium (Triano et al, 2003),
may be relevant. The alcohol dehydrogenase 1B (ADH1B) gene
(formerly called ADH2) exhibits genetic polymorphisms resulting
in altered functional and catalytic properties in vitro (Agarwal,
2001). A strongly increased oxidation capability has been
associated with the *2 allele (Bosron et al, 1983; Eriksson et al,
2001), an Arg47His substitution with reported allele frequencies
ranging between 0 and 6.8% in Europeans (Brennan et al, 2004).
Previously, a significant inverse association between the
ADH1B*2 allele and frequency of alcohol consumption was
observed in a case-only study (Sturmer et al, 2002). We employed
a population-based case–control study of women up to age 50
years to examine the potential effect of ADH1B genotype on the
association between alcohol consumption and breast cancer risk.
MATERIALS AND METHODS
Study subjects and data collection
A detailed description of the underlying case–control study has
been provided elsewhere (Chang-Claude et al, 2000). Patients up to
age 50 years with a diagnosis of primary incident in situ or
invasive breast cancer were recruited between 1 January 1992 and
31 December 1995. Controls were selected randomly from lists of
residents supplied by population registries; for each patient, two
controls were matched according to exact age and study region.
Written informed consent from all participants was obtained. The
study was approved by the ethics committee of the University of
Heidelberg.
In total, 706 (70.2%) women of the 1005 breast cancer patients
who were alive when identified completed the study questionnaire.
Of all 2257 eligible controls, 1381 (61.2%) participated. Detailed
information on demographic characteristics and various risk
factors was elicited by means of a self-administered questionnaire.
Alcohol consumption was assessed for three time periods, that is,
15–20, 20–30 and 30–50 years, and for different types of
beverages (beer, wine, aperitifs, liquor and spirits). The detailed
method for the calculation of average daily alcohol intake has been
described previously (Kropp et al, 2001).
Menopausal status was defined as the reported state half a year
before the reference date, which was the date of diagnosis for cases
and the date of completion of the questionnaire for controls. The
status of women with previous hysterectomy not accompanied by
bilateral oophorectomy was classified as unknown.
The present analysis was restricted to 613 cases and 1082 controls
with at least one parent of German nationality and who could be
successfully genotyped (three and five failures, respectively).
Genotyping ADH1B by TaqMan PCR
Genomic DNA was extracted from peripheral blood using the
QIAamp DNA Blood Kit (Qiagen, Hilden, Germany). Primer and
hybridisation probes were designed with Primer Express. Sense
primer 50-CTCTTTATTCTGTAGATGGTGGCTGTAG-30 and anti-
sense primer 50-GGGTCACCAGGTTGCCACTA-30 were used to
amplify a 76bp fragment containing the G47A polymorphism of
the ADH1B gene. Two minor-groove-binding (MGB) DNA probes
were synthesised. The probe corresponding to the wild type
(50-FAM-TCTGTCGCACAGATG-MGB-30) was labelled with
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y6-FAM, and the probe corresponding to the mutation (50-VIC-
AATCTGTCACACAGATGA-MGB-30) was labelled with VIC at the
50-end. The genotypes were analysed in software ‘Sequence
Detector’ version 1.7 by procedure allelic discrimination after PCR.
Amplification was performed in a final volume of 25ml
containing 40ng of DNA, 300nM of each primer, 200nM of each
probe and 12.5ml of TaqMan Universal PCR Master Mix (Perkin-
Elmer, Weiterstadt, Germany).
In every assay, negative controls as well as controls for the
wild type, mutant type and heterozygote were included. The PCR
conditions were as follows: 2min at 501C plus 951C for 10min,
followed by 40 cycles of denaturation at 921C for 15s, annealing
and extension in one step at 601C for 1min. Genotyping was




2 tests were used to assess deviation from Hardy–Weinberg
equilibrium. Multivariate conditional logistic regression analysis
with 5-year age strata was carried out using the PHREG procedure
of the statistical software package SAS release 8.2 (SAS Institute,
Cary, NC, USA).
In the multivariate model, we included several relevant variables
influencing breast cancer risk (see Table 2). Variables that did not
alter the estimates substantially, such as study region, body mass
index, use of oral contraceptives and age at menarche, were not
included in the analyses presented. Statistical interaction between
ADH1B genotype and alcohol consumption was tested by using
multiplicative interaction terms and evaluated by the likelihood
ratio test.
RESULTS
Selected characteristics of the study population are depicted in
Table 1. In all, 65 breast cancer patients (10.6%) and 109 controls
(10.1%) were heterozygous or homozygous carriers of the
ADH1B*2 allele, corresponding to allele frequencies of 0.06 and
0.05, respectively. The distribution of ADH1B genotypes was in
Hardy–Weinberg equilibrium (P¼0.4 for cases and P¼0.6 for
controls).
We did not observe an association between ADH1B genotype
and several risk factors, including first-degree family history of
breast cancer, body mass index, parity, breastfeeding or smoking
status (data not shown). However, alcohol consumption was found
to differ significantly by ADH1B genotype among controls, with a
mean average daily alcohol intake of 7.2g (standard deviation
(s.d.) 9.1) in women with ADH1B*1/*1 genotype and 5.8g (s.d. 7.8)
in carriers of the *2 allele (Wilcoxon’s rank-sum test P¼0.01).
Results were virtually identical when all study subjects were
considered (data not shown).
The analysis revealed no main effect of ADH1B genotype on
breast cancer risk (adjusted OR for carriers of ADH1B*2 allele vs
ADH1B*1/*1 genotype being 1.0, 95% confidence interval (CI) 0.7–
1.4). However, multivariate analysis separately for carriers and
noncarriers of the ADH1B*2 allele yielded differences in breast
cancer risk associated with increasing levels of alcohol intake
(Table 2). Among carriers of the *2 allele, there was a significant
decreasing trend in breast cancer risk with increasing alcohol
consumption (P-value for linear trend 0.04), although the odds
ratio (OR) was significant only for the category of 12g or more
alcohol per day. In contrast, among women with ADH1B*1/*1
genotype, breast cancer risk increased with increasing alcohol
consumption (P¼0.03). The interaction between ADH1B genotype
and alcohol intake was borderline statistically significant for the
highest category of alcohol consumption (P¼0.05) but not for low
or moderate levels.
DISCUSSION
Our data raise the possibility of an effect modification of the
association between alcohol consumption and breast cancer risk
by ADH1B genotype in our study population, which was apparent
only at the highest consumption category of 12g or more alcohol
per day. We showed previously that breast cancer risk increased
significantly with high daily alcohol intake of X19g in this study
population (Kropp et al, 2001). Owing to the small number of
ADH1B*2 carriers, we were not able to further subdivide the
highest alcohol intake category of X12gday
 1. Corresponding to a
previous case-only study (Sturmer et al, 2002), a case-only analysis
of our data would yield a statistically significant interaction OR
(OR 0.2, 95% CI 0.1–0.6 for X12g alcoholday
 1). However, since
ADH1B genotype and alcohol intake are not independent in our
study population, the modifying effect of the ADH1B genotype on
breast cancer risk associated with alcohol consumption is
overestimated in the case-only analysis, partly due to residual
confounding by differences in alcohol consumption caused by the
genotype (Albert et al, 2001). Indeed, indications for an association
between ADH1B genotype and alcohol consumption, alcoholism or






Mean age (s.d.) 42.4 (5.8) 42.6 (5.7)
Menopausal status
Premenopausal 483 78.8 874 80.8
Postmenopausal 34 5.6 67 6.2
Unknown 96 15.7 141 13.0 0.30
First-degree family history
No 536 87.4 1024 94.6
Yes 77 12.6 58 5.4 o0.01
Parity
0 136 22.2 228 21.1
1–2 children 414 67.5 680 62.9
3+ children 63 10.3 174 16.1 o0.01
Breastfeeding
b
0 153 32.1 247 28.9
1–12 months 289 60.6 501 58.7
12+ months 35 7.3 106 12.4 0.01
Education
Low 80 13.1 149 13.8
Intermediate 412 67.2 679 62.8
High 121 19.7 254 23.5 0.15
Smoking
Never active 271 44.2 515 47.6
Former smoker 132 21.5 258 23.8
Current smoker 210 34.3 309 28.6 0.05
Alcohol consumption (gday on average
 1)
0 117 19.1 176 16.3
1–5 233 38.0 454 42.0
6–11 113 18.4 239 22.1
12+ 150 24.5 213 19.7 0.02
ADH1B genotypes
*1/*1 548 89.4 973 89.9
*1/*2 62 10.1 107 9.9
*2/*2 3 0.5 2 0.2 0.53
c
s.d.¼standard deviation; ADH1B¼alcohol dehydrogenase 1B.
aw
2 test used.
bAmong parous women only.
cFisher’s exact test used.
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yadverse reactions such as flushing were observed in previous
studies (Whitfield et al, 1998; Borras et al, 2000; Loew et al, 2003;
Neumark et al, 2004).
There is still controversy in the literature regarding the effect of
ADH1B genotype on alcohol pharmacokinetics in vivo. Most
studies failed to detect differences in blood alcohol or acetaldehyde
levels by ADH1B genotype (Yamamoto et al, 1993; Mizoi et al,
1994; Whitfield et al, 2001); only one recent study reported a
significantly higher alcohol elimination rate in carriers of the
ADH1B*2 allele (Neumark et al, 2004).
The reduction in breast cancer risk associated with high
consumption levels in carriers of the ADH1B*2 allele in our study
could therefore be explained by a higher alcohol elimination rate
in these subjects. Owing to the low allele frequency of the
ADH1B*2 allele in Caucasians, our study had limited power to
detect a gene–environment interaction for high alcohol consump-
tion levels and our findings about ADH1B genotype as an effect
modifier of breast cancer risk associated with high alcohol
consumption need confirmation in larger studies.
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